Toujeo (insulin glargine injection) was approved in 2015 and is an injectable long-acting insulin. It is used for adults with type 1 or type 2 diabetes to improve glycemic control. It is ...

Insulin glargine is produced by recombinant DNA technology ... 4 to 6.7. It results in an insulin molecule less soluble at the injection site, that precipitates in the subcutaneous tissue forming ...

Such forward looking statements may include statements about the approval for the first interchangeable biosimilar Semglee (insulin glargine-yfgn injection) for the treatment of diabetes ...

The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...

Fröhlich-Reiterer and colleagues, therefore, compared the effects of insulin glargine in several regimens of three injections daily in prepubertal children. This randomized, crossover study ...

Insulin glargine, at a therapeutic concentration ... These molecular changes cause the drug to precipitate upon subcutaneous injection, increasing stability and duration of action.